Scienture Holdings, Inc. (SCNX) Stock Score, Valuation & Financial Research
Scienture Holdings, Inc. is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for SCNX
Scienture Holdings, Inc. currently has a Wall Street Score of 19/100. The stored market price is $0.35. Its financial score is 23/100. Its valuation score is 0/100. The latest WSS change is +1.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Scienture Holdings, Inc. does
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
SCNX financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $0.35
- Market capitalization:
- $14.1M
- Revenue:
- $821K
- Net income:
- $-38.0M
- Free cash flow:
- $-13.4M
- Cash:
- $8.2M
- Total debt:
- $10.7M
- EPS:
- -1.85
- Financial score:
- 23/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.9%.
- Free cash flow is $-13.4M, showing cash burn in the current stored period.
- The balance sheet shows $8.2M of cash versus $10.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +1.4 points: SCNX increased 1.4 points because Revenue improved by 9.1 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research SCNX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.